Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice.

by Henning Lauterbach, Ronny Kassub, Juliane Pätzold, Jana Körner, Michael Brückel, Admar Verschoor, Paul Chaplin, Mark Suter, Hubertus Hochrein
Published 2010-01-01

A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.

by Sonia T Wennier, Kay Brinkmann, Charlotte Steinhäußer, Nicole Mayländer, Claudia Mnich, Ursula Wielert, Ulrike Dirmeier, Jürgen Hausmann, Paul Chaplin, Robin Steigerwald
Published 2013-01-01

Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population.

by Eva-Maria Zitzmann-Roth, Frank von Sonnenburg, Stephan de la Motte, Nathaly Arndtz-Wiedemann, Alfred von Krempelhuber, Nadine Uebler, Jens Vollmar, Garth Virgin, Paul Chaplin
Published 2015-01-01

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory

by Pedro Berraondo, Ignacio Melero, Jose Medina-Echeverz, Maria Hinterberger, Raphael Giessel, Giovanna Fiore, Fabienne Graebnitz, Barbara Bathke, Sonia Wennier, Paul Chaplin, Mark Suter, Henning Lauterbach, Hubertus Hochrein
Published 2021-02-01

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

by José Medina-Echeverz, Maria Hinterberger, Marco Testori, Marlene Geiger, Raphael Giessel, Barbara Bathke, Ronny Kassub, Fabienne Gräbnitz, Giovanna Fiore, Sonia T. Wennier, Paul Chaplin, Mark Suter, Hubertus Hochrein, Henning Lauterbach
Published 2019-11-01

NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin

by Stephanie L. Sanos, Ronny Kassub, Marco Testori, Marlene Geiger, Juliane Pätzold, Raphael Giessel, Johanna Knallinger, Barbara Bathke, Fabienne Gräbnitz, Kay Brinkmann, Paul Chaplin, Mark Suter, Hubertus Hochrein, Henning Lauterbach
Published 2018-01-01

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

by Edgar Turner Overton, Steven J Lawrence, Eva Wagner, Katrin Nopora, Siegfried Rösch, Philip Young, Darja Schmidt, Christian Kreusel, Sonja De Carli, Thomas P Meyer, Heinz Weidenthaler, Nathaly Samy, Paul Chaplin
Published 2018-01-01

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Derma...

by Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin
Published 2015-01-01

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old S...

by Richard N Greenberg, Christine M Hay, Jack T Stapleton, Thomas C Marbury, Eva Wagner, Eva Kreitmeir, Siegfried Röesch, Alfred von Krempelhuber, Philip Young, Richard Nichols, Thomas P Meyer, Darja Schmidt, Josef Weigl, Garth Virgin, Nathaly Arndtz-Wiedemann, Paul Chaplin
Published 2016-01-01

Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed...

by Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin
Published 2015-01-01